Back to today’s briefing

Story perspectives

Librela Faces Backlash After 3,600 Adverse Reactions

5/2/2025

45 5

Summary

Story summary

Librela, a monoclonal antibody for dogs suffering from osteoarthritis, is under fire after over 3,600 adverse reactions, including seizures and fatalities, emerged since its FDA approval in May 2023. Heartbroken owners, like Barbara and George Anderson, recount their pets' harrowing experiences, calling for caution as Zoetis responds to these alarming reports.

1 of 1

Story summary

Librela, a monoclonal antibody for dogs suffering from osteoarthritis, is under fire after over 3,600 adverse reactions, including seizures and fatalities, emerged since its FDA approval in May 2023. Heartbroken owners, like Barbara and George Anderson, recount their pets' harrowing experiences, calling for caution as Zoetis responds to these alarming reports.